Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Novartis Buys Sickle Cell Disease Startup for Up to $665M

By Ryan Bushey | November 22, 2016

Novartis is boosting its hematology pipeline with a new acquisition.

The pharmaceutical giant announced on Monday it would buy Selexys Pharmaceuticals, an Oklahoma-based biotech specializing drug development for certain hematological and inflammatory disorders, in a deal worth up to $665 million.

The startup initially gave Novartis a buyout option in 2012, which hinged upon results from a Phase 2 clinical trial evaluating a sickle cell disease treatment candidate named SelG1. It belongs to a class of drugs known as anti-P-selectin antibodies.

Investigators running this study wanted to see if this drug could help reduce the rate of sickle-cell related pain crises. These events occur when the sickle-cell shaped red blood cells obstruct the flow of blood through the blood vessels, according to Endpoints News.

The trial enrolled 198 people with sickle cell disease where participants either received one of two doses of the drug or a placebo over the course of one year.

“In the cohort that received the high dose of SelG1, the median annual rate of pain crises clocked in at 1.6. The rate in the placebo arm was 3.0. That 47% difference was enough for the study to meet its primary endpoint,” explained FierceBiotech regarding the outcome of this trial.

More details from this study will be presented at the upcoming American Society of Hematology Annual Meeting beginning on December 4th.

Next steps

This deal could help Novartis as it seeks to expand its product offerings because treatnents for blood disease could command high prices due to high demand, wrote Reuters. 

Treatments for blood disease could command high prices due to high demand, wrote Reuters.

However, some analysts felt the pharmaceutical giant needed to do better at convincing investors it was on the right path towards growth as it struggles with low sales for heart failure drug Entresto and the patent expiration for lucrative cancer drug Gleevec.

“It’s definitely an improvement of the hematology pipeline within the oncology business, but it’s not exactly a bargain and it won’t have any influence on the share price,” explained Zuercher Kantonalbank analyst Michael Nawrath in a note to investors.

Shares of Novartis were down 0.85 percent in mid-day trading.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE